VRTX · News · 20260807N

Revenue Performance and Mix

VERTEX PHARMACEUTICALS INC / MA · 2026-08-07 · Importance 36 · Surprise 40

Vertex’s second-quarter 2026 revenue increased 12% year over year to $3.33 billion. Cystic fibrosis therapies remained the primary growth driver, while CASGEVY in sickle cell disease and beta thalassemia and JOURNAVX in acute pain added to product diversification. Revenue exceeded analyst expectations, although quarterly earnings per share were below consensus. Vertex raised its full-year 2026 revenue guidance to $13.1 billion-$13.2 billion.

Key facts

• PensionDanmark increased its stake in Vertex by 9.9% in the second quarter to 54,094 shares valued at $26.9 million. source